SUBSCRIBE
SUBSCRIBE
News   Business

GlaxoSmithKline (JOBS) to Pay Actelion Ltd. up to $3.3 Billion for Drug Rights

July 14, 2008 | 
1 min read
ZURICH (Reuters) - GlaxoSmithKline Ltd could pay Swiss company Actelion Ltd up to 3.3 billion Swiss francs ($3.28 billion) to develop a promising insomnia drug in the largest biotech partnering deal.
Alliances Mergers & acquisitions Europe
MORE ON THIS TOPIC
One Death in the HAVEN 1 Trial Complicates Roche’s Entry into the Hemophilia A Market
Mergers & acquisitions
Roche Makes Major MASH Move With $3.5B 89bio Buy
September 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Arsenal, X4 Lay Off Half of Staff to Cut Costs
September 18, 2025
 · 
200 min read
 · 
BioSpace Editorial Staff
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Innate Sheds 30% of Staff, Narrows Pipeline Focus Amid ‘Challenging Funding Environment’
September 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Businessman tied up with red tape. concept of struggle, limitation and trap or challenge
FDA
FDA’s Ad Crackdown Targets Novo, Lilly’s Oprah Special on GLP-1s
September 17, 2025
 · 
3 min read
 · 
Annalee Armstrong